Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
RCT	107 people with predominantly negative symptoms	Mean change from baseline in Positive and Negative Syndrome Scale (PANSS) negative subscore 8 weeks with risperidone (2–6 mg/day) with flupentixol (4–12 mg/day) Absolute results not reported	Mean difference –1.11 95% CI –3.30 to +1.07		Not significant
RCT	107 or fewer people with predominantly negative symptoms	Mean change from baseline in PANSS negative subscore 16 weeks with risperidone (2–6 mg/day) with flupentixol (4–12 mg/day) Absolute results not reported	Mean difference +0.10 95% CI –2.69 to +2.90		Not significant
RCT	107 or fewer people with predominantly negative symptoms	Mean change from baseline in PANSS negative subscore 24 weeks with risperidone (2–6 mg/day) with flupentixol (4–12 mg/day) Absolute results not reported	Mean difference +1.60 95% CI –1.63 to +4.83		Not significant
RCT	107 people with predominantly negative symptoms	Change from baseline in PANSS positive score 24 weeks with risperidone (2–6 mg/day) with flupentixol (4–12 mg/day) Absolute results not reported	P >0.05		Not significant